Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Association between elevated cytokeratin 18 (CK-18) levels and hepatocyte death has made circulating CK-18 a candidate biomarker to differentiate non-alcoholic fatty liver from non-alcoholic steatohepatitis (NASH). Yet studies produced variable diagnostic performance. We aimed to provide summary estimates with increased precision for the accuracy of CK-18 (M30, M65) in detecting NASH and fibrosis among non-alcoholic fatty liver disease (NAFLD) adults. METHODS: We searched five databases to retrieve studies evaluating CK-18 against a liver biopsy in NAFLD adults. Reference screening, data extraction and quality assessment (QUADAS-2) were independently conducted by two authors. Meta-analyses were performed for five groups based on the CK-18 antigens and target conditions, using one of two methods: linear mixed-effects multiple thresholds model or bivariate logit-normal random-effects model. RESULTS: We included 41 studies, with data on 5,815 participants. A wide range of disease prevalence was observed. No study reported a pre-defined cut-off. Thirty of 41 studies provided sufficient data for inclusion in any of the meta-analyses. Summary AUC [95% CI] were: 0.75 [0.69-0.82] (M30) and 0.82 [0.69-0.91] (M65) for NASH; 0.73 [0.57-0.85] (M30) for fibrotic NASH; 0.68 (M30) for significant (F2-4) fibrosis; and 0.75 (M30) for advanced (F3-4) fibrosis. Thirteen studies used CK-18 as a component of a multimarker model. CONCLUSIONS: For M30 we found lower diagnostic accuracy to detect NASH compared to previous meta-analyses, indicating a limited ability to act as a stand-alone test, with better performance for M65. Additional external validation studies are needed to obtain credible estimates of the diagnostic accuracy of multimarker models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent meta-analysis proposed K-18 values between 127–191 U l−1 for ruling-out MASH at fixed sensitivity levels and 304–399 U l−1 to rule-in MASH at fixed specificity levels32.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199 · cited 1×
“The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [18] was used to assess methodological quality of all available full text studies.”
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAFLD Activity Score (NAS) [16] is the most commonly used pathologic criterion for evaluating NASH.”
MethodYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 4×
“He reports research grant funding from Abbvie, Allergan/ Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex; consultancy on behalf of Newcastle University for Abbott Laboratories, Acuitas Medical, Allergan/ Tobira, Blade, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Co…”
BackgroundInfluentialEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369 · cited 1×
“Heterogeneity between and within studies was incorporated by calculating 95% prediction intervals [20].”
MethodSelf-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · cited 1×
“Fibrosis is the strongest predictor for long-term clinical outcomes in NAFLD patients, thereby, a key target event for patient stratification and clinical trial recruitment [4].”
BackgroundSampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293 · cited 1×
“Parameters such as mean age, BMI and disease prevalence were not sources of major heterogeneity between the present and previously published meta-analyses [61].”
ResultYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073 · cited 4×
“He reports research grant funding from Abbvie, Allergan/ Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex; consultancy on behalf of Newcastle University for Abbott Laboratories, Acuitas Medical, Allergan/ Tobira, Blade, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Co…”
BackgroundInfluentialFeldstein, A. E., Wieckowska, A., Lopez, R. A., Liu, Y.-C., Zein, N. N., & McCullough, A. J. (2009) · Hepatology · doi:10.1002/hep.23050 · Cited by 712 · cited 3×
“Feldstein 2009 [8] USA 139 (88) NASH 50 Biopsy proven NAFLD 34.”
Background
Cited by
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
“A recent meta-analysis proposed K-18 values between 127–191 U l −1 for ruling-out MASH at fixed sensitivity levels and 304–399 U l −1 to rule-in MASH at fixed specificity levels 32 .”
BackgroundDuseja, A. K., Singh, S. P., De, A., Madan, K., Rao, P. N., Shukla, A., Choudhuri, G., Saigal, S., Shalimar, S., Arora, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.014 · Cited by 117
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
Qadri, S. U., Ahlholm, N., Lønsmann, I., Pellegrini, P., Poikola, A., Luukkonen, P. K., Porthan, K., Juuti, A., Sammalkorpi, H. E., Penttilä, A. K., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab933 · Cited by 67
Epigenetics of Hepatic Insulin Resistance
Maude, H., Sanchez-Cabanillas, C., & Cebola, I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.681356 · Cited by 69
Metadata
- Authors
- Lee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Centre Hospitalier Universitaire d'Angers (FR)
- Eli Lilly (United States) (US)
- Pfizer (United States) (US)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Corresponding author
- Lee, Jenny
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-09-11
- Volume
- 15
- Issue
- 9
- Pages
- e0238717
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7485872
- OpenAlex
- W3084487116
- Cited by
- 74
- References
- 66
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 15 · 2023: 20 · 2022: 12 · 2021: 11
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Innovative Medicines Initiative (777377)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- cytokeratin 18, M30, M65, nonalcoholic steatohepatitis, liver fibrosis, non-alcoholic fatty liver disease, circulating biomarkers, diagnostic accuracy, hepatocyte death, liver biopsy
- MeSH terms
- Adult, Biopsy, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Peptide Fragments, Biomarkers, Cell Death, Hepatocytes, Keratin-18, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0238717
- The paper
- Lee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020). Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0238717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.